卡托普利、血管紧张素Ⅱ与糖尿病性视网膜病变  

CAPTOPRIL THERAPY AND THE ACTION OF ANGIOTENSINⅡ ON DIABETIC RETINOPATHY

作　　者：刘秀兰[1] 高莉莉[2] 

机构地区：[1]内蒙古医学院附属医院,内蒙古呼和浩特010050 [2]内蒙古医学院第三附属医院眼科

出　　处：《内蒙古医学院学报》2008年第2期97-100,共4页Acta Academiae Medicinae Neimongol

摘　　要：目的:探讨血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)在糖尿病性视网膜病变(diabetic retinopathy,DR)发生、发展中的作用和卡托普利对AngⅡ及DR的影响。方法:采用同位素(125I)放射免疫测定法(radioimmunoas-say,RIA)测定血浆AngⅡ浓度。结果:1.血浆AngⅡ浓度,PDR组与BDR组比较,无差异,均高于NDR组,NDR组高于CG组。2.12wk后复查,服药组血浆AngⅡ浓度较不服药组降低。结论:1.血浆AngⅡ浓度随病变的加重而增高,参与DR的发生、发展。2.卡托普利使BDR病人血浆AngⅡ浓度有下降趋势,且用药组有效率高于不用药组,提示血管紧张素转化酶抑制药ACEI可能成为防治威胁视功能的DR的有效手段之一。Objective： To study the relationship between angiotensin Ⅱ （ Ang Ⅱ ） and the occurrence or progression of diabetic retinopathy（DR） and the therapeutical effect of captopril in diabetic retinopathy（DR）. Methods：The Ang Ⅱ concentration was measured by radioimmunoassay （RIA）. Results： 1. Plasma Ang Ⅱ levels in PDR and BDR were higher than that in NDR. Plasma Ang Ⅱ levels in CG were the lowest. And plasma Ang Ⅱ levels in PDR was not different from that in BDR. 2. After 12 weeks, the plasma Ang Ⅱ levels in captopril group were lower than that in control group. Conclusion ： 1. Ang Ⅱ may play an important role in the onset and development of DR. 2. Captopril can reduce the plasma Ang Ⅱ levels for BDR. The effect of treatment in captopril group was better than that in control group. Angiotensin converting enzyme inhibitors probably become one of ways to treat DR.

关 键 词：糖尿病视网膜病变 血管紧张素Ⅱ 卡托普利 

分 类 号：R771.3[医药卫生—眼科]